18 terminated. 18 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Terminated 18 |
| Phase 2 | 2 | Terminated 2 |
Follow Foot Ulcer: new trials by email Literature Review of Foot Ulcer trials Research Report on Foot Ulcer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs SkinTE, Control - Diabetic Foot | Phase 3 | Terminated | PolarityTE | 42 | 2022-04-28 | 2024-02-26 |
| A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Granexin gel, Vehicle gel - Diabetic Foot Ulcers | Phase 3 | Terminated | Xequel Bio, Inc. | 124 | 2018-11-21 | 2020-05-29 |
| Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers Engensis (VM202), Placebo - Foot Ulcer, Diabetic | Phase 3 | Terminated | Helixmith Co., Ltd. | 44 | 2017-06-27 | 2025-10-09 |
| Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use 0.03% DSC127 topical gel - Diabetic Foot Ulcer | Phase 3 | Terminated | Integra LifeSciences Corporation | 261 | 2015-12-01 | 2017-12-12 |
| Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers DSC127, placebo vehicle gel, Standard of Care gel, Aquasite - Diabetic Foot Ulcers | Phase 3 | Terminated | Integra LifeSciences Corporation | 396 | 2013-04-01 | 2017-12-12 |
| Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers DSC127, placebo vehicle gel - Diabetic Foot Ulcers | Phase 3 | Terminated | Integra LifeSciences Corporation | 266 | 2013-02-01 | 2017-12-12 |
| Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers Royal Jelly and Panthenol (PedyPhar® Ointment), Panthenol Ointment - Diabetic Foot Ulcer | Phase 3 | Terminated | European Egyptian Pharmaceutical Industries | 47 | 2011-07-01 | 2015-02-20 |
| Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment Daptomycin, Vancomycin - Diabetic Foot | Phase 3 | Terminated | Ruhr University of Bochum | 1 | 2011-07-01 | 2024-03-18 |
| Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia urokinase - Diabetic Foot, Critical Limb Ischemia | Phase 3 | Terminated | GWT-TUD GmbH | 34 | 2011-06-01 | 2014-04-07 |
| Urokinase Therapy in Patients With Diabetic Foot Syndrome standard therapy, Urokinase - Diabetic Foot, Arterial Occlusive Disease | Phase 3 | Terminated | medac GmbH | 5 | 2008-06-01 | 2015-03-13 |
| BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers BST-DermOn - Diabetic Foot Ulcer | Phase 3 | Terminated | BioSyntech Canada Inc. | 40 | 2007-02-01 | 2009-02-05 |
| Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers Dermal - Living Skin Replacement (Dermal - LSR) - Diabetic Foot Ulcer | Phase 3 | Terminated | ApoPharma | 288 | 2006-02-01 | 2008-05-02 |
| Efficacy and Safety Study of Dermal-Living Skin Replacement to Treat Diabetic Foot Ulcers Dermal - Living Skin Replacement (Dermal-LSR) - Diabetic Foot Ulcer | Phase 3 | Terminated | University of California, Davis | 20 | 2005-08-01 | 2015-04-07 |
| Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures Remodulin® (treprostinil sodium) Injection - Critical Limb Ischemia, Peripheral Vascular Disease | Phase 3 | Terminated | United Therapeutics | 30 | 2003-02-01 | 2013-03-07 |
| Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients bemiparin (low molecular weight heparin) - Foot Ulcer, Diabetic, Diabetic Angiopathies | Phase 2 / Phase 3 | Terminated | Spanish National Health System | 84 | 2001-06-01 | 2006-11-14 |
| A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX Becaplermin - Foot Ulcer, Diabetic Foot | Phase 3 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 84 | 2000-12-01 | 2011-06-08 |
| Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers Bi-layered cell therapy (Apligraf) - Diabetic Foot | Phase 3 | Terminated | Organogenesis | 82 | 2000-10-01 | 2007-08-07 |
Diabetic Foot (17) · Diabetes Mellitus (5) · Chronic Limb-Threatening Ischemia (2) · Arterial Occlusive Diseases (1) · Diabetes Complications (1) · Diabetic Angiopathies (1) · Diabetic Neuropathies (1) · Ischemia (1) · Peripheral Vascular Diseases (1) · Skin Ulcer (1) · Ulcer (1)
Cardiovascular Diseases (18) · Leg Ulcer (18) · Skin Diseases (18) · Skin and Connective Tissue Diseases (18) · Vascular Diseases (18) · Endocrine System Diseases (17) · Skin Ulcer (17) · Diabetes Complications (16) · Diabetic Angiopathies (16) · Diabetic Neuropathies (16) · Diabetes Mellitus (12) · Glucose Metabolism Disorders (5) · Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5)
Standard of Care (2) · Urokinase-Type Plasminogen Activator (2) · aclerastide (2) · Arginine (1) · Ascorbic Acid (1) · Becaplermin (1) · Daptomycin (1) · Fatty Acids, Omega-3 (1) · Heparin, Low-Molecular-Weight (1) · Injections (1) · Ointments (1) · Omacor (1) · Vancomycin (1) · bemiparin (1) · dexpanthenol (1)
Integra LifeSciences Corporation (3) · ApoPharma (1) · BioSyntech Canada Inc. (1) · European Egyptian Pharmaceutical Industries (1) · GWT-TUD GmbH (1) · Helixmith Co., Ltd. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Organogenesis (1) · PolarityTE (1) · Prisma Health-Midlands (1) · Ruhr University of Bochum (1) · Spanish National Health System (1) · United Therapeutics (1) · University of California, Davis (1) · Xequel Bio, Inc. (1)
United States (10) · Canada (3) · Germany (3) · Egypt (1) · Hungary (1) · India (1) · Poland (1) · Puerto Rico (1) · South Africa (1)
Roslyn R Isseroff, M.D. (2) · Adam Landsman, DPM, PhD (1) · Alan Dunton, MD (1) · Alberto Restrepo, M.D. (1) · David Armstrong, DPM, MD, PhD (1) · David G Armstrong,, DPM, MD, PhD (1) · Diethelm Tschoepe, Prof Dr Dr (1) · Emerson C. Perin, MD (1) · Georgeanne Botek, DPM (1) · Hau Pham, DPM (1) · Henryk Komon (1) · Hesham M Abdel Samad, PhD (1) · J. Benjamin Jackson, MD (1) · Jason R Hanft, DPM, FAC FAS (1)